Literature DB >> 29702232

Biopharmaceutical evaluation of surface active ophthalmic excipients using in vitro and ex vivo corneal models.

Marina Juretić1, Biserka Cetina-Čižmek2, Jelena Filipović-Grčić3, Anita Hafner3, Jasmina Lovrić3, Ivan Pepić4.   

Abstract

The objective of this study was to systematically investigate the effects of surface active ophthalmic excipients on the corneal permeation of ophthalmic drugs using in vitro (HCE-T cell-based model) and ex vivo (freshly excised porcine cornea) models. The permeation of four ophthalmic drugs (i.e., timolol maleate, chloramphenicol, diclofenac sodium and dexamethasone) across in vitro and ex vivo corneal models was evaluated in the absence and presence of four commonly used surface active ophthalmic excipients (i.e., Polysorbate 80, Tyloxapol, Cremophor® EL and Pluronic® F68). The concentration and self-aggregation-dependent effects of surface active ophthalmic excipients on ophthalmic drug permeability were studied from the concentration region where only dissolved monomer molecules of surface active ophthalmic excipients exist, as well as the concentration region in which aggregates of variable size and dispersion are spontaneously formed. Neither the surface active ophthalmic excipients nor the ophthalmic drugs at all concentrations that were tested significantly affected the barrier properties of both corneal models, as assessed by transepithelial electrical resistance (TEER) monitoring during the permeability experiments. The lowest concentration of all investigated surface active ophthalmic excipients did not significantly affect the ophthalmic drug permeability across both of the corneal models that were used. For three ophthalmic drugs (i.e., chloramphenicol, diclofenac sodium and dexamethasone), depressed in vitro and ex vivo permeability were observed in the concentration range of either Polysorbate 80, Tyloxapol, Cremophor® EL or Pluronic® F68, at which self-aggregation is detected. The effect was the most pronounced for Cremophor® EL (1 and 2%, w/V) and was the least pronounced for Pluronic® F68 (1%, w/V). However, all surface active ophthalmic excipients over the entire concentration range that was tested did not significantly affect the in vitro and ex vivo permeability of timolol maleate, which is the most hydrophilic ophthalmic drug that was investigated. The results of the dynamic light scattering measurements point to the association of ophthalmic drugs with self-aggregates of surface active ophthalmic excipients as the potential mechanism of the observed permeability-depressing effect of surface active ophthalmic excipients. A strong and statistically significant correlation was observed between in vitro and ex vivo permeability of ophthalmic drugs in the presence of surface active ophthalmic excipients, which indicates that the observed permeability-altering effects of surface active ophthalmic excipients were comparable and were mediated by the same mechanism in both corneal models.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Drug permeability; HCE-T; In vitro and ex vivo corneal models; Self-aggregation; Surfactants

Mesh:

Substances:

Year:  2018        PMID: 29702232     DOI: 10.1016/j.ejps.2018.04.032

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  6 in total

Review 1.  Fluorescent Nanosystems for Drug Tracking and Theranostics: Recent Applications in the Ocular Field.

Authors:  Elide Zingale; Alessia Romeo; Salvatore Rizzo; Cinzia Cimino; Angela Bonaccorso; Claudia Carbone; Teresa Musumeci; Rosario Pignatello
Journal:  Pharmaceutics       Date:  2022-04-28       Impact factor: 6.525

2.  New Approach in Ocular Drug Delivery: In vitro and ex vivo Investigation of Cyclodextrin-Containing, Mucoadhesive Eye Drop Formulations.

Authors:  Tivadar Bíró; Alexandra Bocsik; Bisera Jurišić Dukovski; Ilona Gróf; Jasmina Lovrić; Ildikó Csóka; Mária A Deli; Zoltán Aigner
Journal:  Drug Des Devel Ther       Date:  2021-02-03       Impact factor: 4.162

3.  PLGA Nanoparticle Platform for Trans-Ocular Barrier to Enhance Drug Delivery: A Comparative Study Based on the Application of Oligosaccharides in the Outer Membrane of Carriers.

Authors:  Ge Jiang; Huanhuan Jia; Jindi Qiu; Junfeng Ban; Zhenjie Mo; Yifeng Wen; Yan Zhang; Yuqin Wen; Qingchun Xie; Zhufen Lu; Yanzhong Chen; Hao Wu; Qingchun Ni; Fohua Chen; Jiashu Lu; Zhijiong Wang; Haoting Li; Junming Chen
Journal:  Int J Nanomedicine       Date:  2020-11-24

4.  Self-nanoemulsifying drug delivery system of bruceine D: a new approach for anti-ulcerative colitis.

Authors:  Yao-Xing Dou; Jiang-Tao Zhou; Tong-Tong Wang; Yan-Feng Huang; Vicky Ping Chen; You-Liang Xie; Zhi-Xiu Lin; Jian-Sheng Gao; Zi-Ren Su; Hui-Fang Zeng
Journal:  Int J Nanomedicine       Date:  2018-09-28

5.  SCD1-Fatty Acid Desaturase Inhibitor MF-438 Alleviates Latent Inflammation Induced by Preservative-Free Prostaglandin Analog Eye Drops.

Authors:  Anna Pacwa; Joanna Machowicz; Alicja Wojtyniak; Marita Pietrucha-Dutczak; Elisa Toropainen; Ali Koskela; Ewa Mrukwa-Kominek; Joanna Lewin-Kowalik; Adrian Smedowski
Journal:  J Inflamm Res       Date:  2022-02-08

6.  Ex Vivo Conjunctival Retention and Transconjunctival Transport of Poorly Soluble Drugs Using Polymeric Micelles.

Authors:  Silvia Pescina; Leticia Grolli Lucca; Paolo Govoni; Cristina Padula; Elena Del Favero; Laura Cantù; Patrizia Santi; Sara Nicoli
Journal:  Pharmaceutics       Date:  2019-09-14       Impact factor: 6.321

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.